Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Utility of oral valganciclovir for the treatment of cytomegalovirus disease after renal transplantation

Nature Clinical Practice Nephrology volume 4, pages 18–19 (2008)Cite this article

Access through your institution
Buy or subscribe

boxed-textAsberg A et al. (2007) Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7: 2106–2113

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

References

  1. Fishman JA et al. (2007) Cytomegalovirus in transplantation—challenging the status quo. Clin Transplant 21: 149–158

    Article  PubMed  Google Scholar 

  2. [No authors listed] (2004) Cytomegalovirus. Am J Transplant 4 (Suppl 10): S51–S58

  3. Preiksaitis JK et al. (2005) Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5: 218–227

    Article  PubMed  Google Scholar 

  4. Paya C et al. (2004) Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4: 611–620

    Article  CAS  PubMed  Google Scholar 

  5. Humar A et al. (2005) A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 192: 1154–1157

    Article  CAS  PubMed  Google Scholar 

  6. Mattes FM et al. (2005) Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 191: 89–92

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. David Geffen School of Medicine at UCLA, Division of Infectious Diseases, 37-121 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1688, USA dpegues@mednet.ucla.edu

Authors and Affiliations

  1. DA Pegues is a Professor of Clinical Medicine and Hospital Epidemiologist at the David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.,

    David A Pegues

Authors
  1. David A Pegues
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pegues, D. Utility of oral valganciclovir for the treatment of cytomegalovirus disease after renal transplantation. Nat Rev Nephrol 4, 18–19 (2008). https://doi.org/10.1038/ncpneph0642

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpneph0642

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing